STEP: Fingolimod in Schizophrenia Patients

• Sponsor: Indiana University (Other)
• Overall Status: Completed
• CT.gov ID: NCT01779700
• Collaborator: (none)
• Enrollment: 40
• Locations: 3
• Arms: 2
• Actual Duration (Months): 43
• Patients Per Site: 13.3
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo for duration of 8 weeks.

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia	Drug: Fingolimod; Drug: placebo	Phase 2

Detailed Description

Study Design:

This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo for duration of 8 weeks.

All subjects will be admitted to the Indiana Clinical and Translational Sciences Institute Clinical Research Center (CRC) and remain hospitalized for the first 24 (+/- 2) hours post initial dose of study medication. The CRC is located in Indiana University Hospital and has 24 hour staffing with nurses skilled in conducting Phase 1 and Phase 2 investigational drug studies.

Background and Rationale:

Schizophrenia is a severe brain disorder that begins during the teenage years and early twenties and typically progresses to a life-long chronic illness marked by psychotic symptoms, cognitive impairment and poor functioning. A leading hypothesis to account for the symptoms and cognitive dysfunction of this disorder is that abnormalities exist in cortical circuits, particularly in frontal and temporal areas. An interest in cortical circuitry has led to a focus on the integrity of cortical white matter tracts as possibly contributing to the pathophysiology of this illness. Indeed, several lines of evidence have supported abnormalities in white matter structure and function in schizophrenia. Numerous myelin-related genes and their functional expression have been associated with schizophrenia. Moreover, quantitative and qualitative abnormalities in prefrontal cortical oligodendrocytes have been found in postmortem studies. MRI-determined volumetric reductions in prefrontal white matter have been reported in schizophrenia. Advances in MRI technology have enhanced the ability to study white matter pathology in vivo. Diffusion tensor imaging (DTI) and fractional anisotropy (FA) provides an assessment of the density and integrity of white matter tracts. Decreased FA has been reported in many de-myelinating diseases including multiple sclerosis (MS), leukodystrophies, and HIV. Numerous studies using DTI have reported decrements in FA in schizophrenia with the most consistent abnormalities occurring in frontal cortical white matter. Also, FA has been shown to be sensitive to therapeutic drug effects in MS which supports DTI-derived FA as an outcome measure in clinical trials of neuroprotective agents.

Fingolimod (FTY720, approved as Gilenya™ ) is a sphingosine-1-phosphate (S1P) receptor modulator and recently licensed in the USA and several other countries for relapsing forms of multiple sclerosis (MS). It is administered as a once per day oral preparation. In registration clinical trials, it had positive effects on brain atrophy, MRI-determined axonal lesions and relapse rates. Significant improvement in the mean number of MRI assessed T1 gadolinium (Gd) enhanced lesions/patient and the percentage of patients free of T1 Gd-enhanced lesions was observed within 6 months of treatment and there was evidence of clinical improvement as early as 2 months after treatment initiation

Study Design

• Study Type: Interventional
• Actual Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
• Actual Study Start Date: Jan 1, 2013
• Actual Primary Completion Date: Aug 1, 2016
• Actual Study Completion Date: Aug 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Fingolimod 0.5mg of fingolimod, oral administration, daily, for 8 weeks.	Drug: Fingolimod; 0.5mg each day of 8 week cycle; Other Names: gilenya
Placebo Comparator: placebo placebo, oral administration, daily, for 8 weeks.	Drug: placebo; 1 tablet each day of 8 week cycle; Other Names: sugar pill

Outcome Measures

Primary Outcome Measures

1. QTcB Change [Screening, Day 0, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 84, Day 112]

   To determine the safety of fingolimod, as measured by the electrocardiogram (ECG) QT interval corrected by Bazett's (QTcB) value.

2. Levels of Lymphocyte [Baseline, 4 weeks, 8 weeks]

   To determine the safety of fingolimod, as measured by the absolute lymphocyte count

3. Symptom Changes - PANSS Total Score [Baseline, 4 weeks, 8 weeks]

   The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview, containing 30 items that assess symptoms of psychotic disorders including positive, negative, and general psychopathology symptoms. Positive symptoms are rated on 7 items, negative symptoms are rated on 7 items, and general psychopathology on 16 items. Scores for each item range from 1=absent to 7=extreme. Positive, negative, and general psychopathology symptoms can each respectively render total scores. Positive total scores ranging from 7-49, negative total scores ranging from 7-49, and general psychopathology scores ranging from 16-112. When all items are summed together a total score is generated. Total scores for all items range from 30-210, a lower score reflecting fewer symptoms.

Secondary Outcome Measures

1. Verbal Memory - BACS [Baseline, 4 weeks, 8 weeks]

   The Brief Assessment of Cognition in Schizophrenia (BACS) is a battery specifically designed to measure treatment-related changes in cognition. The BACS utilizes 6 tasks, and has alternate forms, thus minimizing practice effects. Each task generates a raw score (with a higher score indicating better performance): verbal memory 0-75; digit sequencing 0-28; token motor task 0-100; semantic&letter fluency 0-148; symbol coding 0-110; and tower of London 0-22. The raw scores are used to generate a composite score that is calculated by summing t-scores derived by comparisons with a normative sample of 404 healthy controls. The six brief assessments' t-scores, are summed, and averaged to provide a composite t-score. The composite score min and max are between -43 and 100. A higher score indicating better cognitive performance.

2. Cognition Change - BACS [Baseline, 4 weeks, 8 weeks]

   The Brief Assessment of Cognition in Schizophrenia (BACS) is a battery specifically designed to measure treatment-related changes in cognition by utilizing 6 tasks, and has alternate forms, thus minimizing practice effects. Each task generates a raw score (with a higher score indicating better performance): verbal memory 0-75; digit sequencing 0-28; token motor task 0-100; semantic&letter fluency 0-148; symbol coding 0-110; and tower of London 0-22. The raw scores are used to generate a composite score that is calculated by summing t-scores derived by comparisons with a normative sample of 404 healthy controls. The six brief assessments' t-scores, are summed, and averaged to provide a composite t-score. The composite score min and max are between -43 and 100. A higher score indicating better cognitive performance.

3. Cognition Change - Trails B [Baseline, 4 weeks, 8 weeks]

   The Trail Making Test-Part B (Trails B) is a measure of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive targets on a sheet of paper. In Part B version the subject alternates between numbers and letters (1, A, 2, B, etc.) The goal of the test is for the subject is to finish part B as quickly as possible, the time taken to complete the test is used as the primary performance metric. The score is the number of seconds it took to complete the test.

4. Positive Symptom Change - PANSS [Baseline, 4 weeks, 8 weeks]

   The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview, containing 30 items that assess symptoms of psychotic disorders including positive, negative, and general psychopathology symptoms. Positive symptoms are rated on 7 items, negative symptoms are rated on 7 items, and general psychopathology on 16 items. Scores for each item range from 1=absent to 7=extreme. Positive, negative, and general psychopathology symptoms can each respectively render total scores. Positive total scores ranging from 7-49, negative total scores ranging from 7-49, and general psychopathology scores ranging from 16-112. When all items are summed together a total score is generated. Total scores for all items range from 30-210, a lower score reflecting fewer symptoms.

5. Negative Symptom Change - PANSS [Baseline, 4 weeks, 8 weeks]

   The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview, containing 30 items that assess symptoms of psychotic disorders including positive, negative, and general psychopathology symptoms. Positive symptoms are rated on 7 items, negative symptoms are rated on 7 items, and general psychopathology on 16 items. Scores for each item range from 1=absent to 7=extreme. Positive, negative, and general psychopathology symptoms can each respectively render total scores. Positive total scores ranging from 7-49, negative total scores ranging from 7-49, and general psychopathology scores ranging from 16-112. When all items are summed together a total score is generated. Total scores for all items range from 30-210, a lower score reflecting fewer symptoms.

6. Plasma Cytokines Levels - IL-10 [Baseline, 4 weeks, 8 weeks]

   To assess IL-10 plasma cytokines levels changes in participants taking fingolimod versus placebo

7. Plasma Cytokines Levels - IL-17A [Baseline, 4 weeks, 8 weeks]

   To assess IL-17A plasma cytokines levels changes in participants taking fingolimod versus placebo

8. Plasma Cytokines Levels - IL-1BETA [Baseline, 4 weeks, 8 weeks]

   To assess IL-1BETA plasma cytokines levels changes in participants taking fingolimod versus placebo

9. Plasma Cytokines Levels - IL-2 [Baseline, 4 weeks, 8 weeks]

   To assess IL-2 plasma cytokines levels changes in participants taking fingolimod versus placebo

10. Plasma Cytokines Levels - IL-4 [Baseline, 4 weeks, 8 weeks]

    To assess IL-4 plasma cytokines levels changes in participants taking fingolimod versus placebo

11. Plasma Cytokines Levels - IL-6 [Baseline, 4 weeks, 8 weeks]

    To assess IL-6 plasma cytokines levels changes in participants taking fingolimod versus placebo

12. Plasma Cytokines Levels - IL-8 [Baseline, 4 weeks, 8 weeks]

    To assess IL-8 plasma cytokines levels changes in participants taking fingolimod versus placebo

13. Plasma Cytokines Levels - TNFa [Baseline, 4 weeks, 8 weeks]

    To assess TNFa plasma cytokines levels changes in participants taking fingolimod versus placebo

14. Plasma Cytokines Levels - IFNgamma [Baseline, 4 weeks, 8 weeks]

    To assess IFNgamma plasma cytokines levels changes in participants taking fingolimod versus placebo

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion

• 18 to 65 yrs, able to give informed consent

• DSM IV-TR Diagnosis of schizophrenia or schizoaffective disorder

• Previous and/or current exposure to one of the following antipsychotic medications (clozapine, olanzapine, risperidone, paliperidone, haloperidol, quetiapine) as defined by a minimum of 8 weeks in duration greater than or equal to the Food and Drug Administration (FDA) approved therapeutic range for schizophrenia at the time of study entry OR previous and/or current exposure to two antipsychotic medications as defined by a minimum of 4 weeks in duration and greater than or equal to the FDA approved therapeutic range for schizophrenia at the time of study entry

• willing to participate in a minimum of 1 day of hospitalization

• Clinical stability:

1. CGI-S score of < 4 at randomization AND

2. no exacerbation of illness within 4 weeks prior to randomization, leading to an intensification of psychiatric care in the opinion of the investigator AND

3. antipsychotic treatment stability for at least 4 weeks prior to randomization

• Female subjects of childbearing potential must test negative for pregnancy at screening and agree to use a single, effective, medically acceptable method of birth control for the duration of the study and for two months following cessation of study medication

• Subjects must agree not to consume tonic water for the duration of the study and for two months following cessation of study medication

• Sub-optimally treated positive OR negative symptoms as defined by the Brief

Psychiatric Rating Scale (BPRS):

1. BPRS positive symptom factor (conceptual disorganization, hallucinations, suspiciousness, unusual thought content) score of > 4 on any one item or a sum > 8 on the factor

2. BPRS negative symptom factor (motor retardation, blunted affect, inappropriate affect) score of > 4 on any one item or a sum > 6 on the factor

Exclusion

• Subjects who are considered prisoners per the IU Standard Operating Procedures for Research Involving Human Subjects

• Current acute, serious, or unstable medical conditions

• Clinically significant electrocardiogram abnormality: corrected QT interval >450 msec (M) or >470 msec (F) prior to randomization OR sinus bradycardia (HR < 50 beats/min)

• Subjects who have experienced the following within the six months prior to study entry: myocardial infarction, unstable angina, stroke, transient ischemic attach (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure

• Hypokalemia, hypomagnesemia, or congenital long-QT syndrome

• Known HIV+ status

• Active seizure disorder

• Pregnant or lactating women or women who plan to become pregnant or will be lactating within two months after cessation of study drug

• Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, ventriculoperitoneal shunt, or other contraindication to undergoing an MRI scan

• Class1a or class 3 antiarrhythmic agents, beta blockers, diltiazem, verapamil, digoxin, tricyclic antidepressants, warfarin, ketoconazole, ketamine

• Subjects likely to need a live attenuated vaccine during the course of the study or within two months after stopping study medication

• Subjects with no history of chicken pox or chicken pox vaccination, or with a negative VZV titer

• Active herpes simplex outbreak, mononucleosis, or zoster

• Subjects with histories of ischemic heart disease, myocardial infarction, congestive heart failure, cardiac arrest, cerebrovascular disease, unexplained or recurrent syncope, cardiac conduction prolongations (prolonged P-R interval), cardiac arrhythmias, symptomatic bradycardia, or severe untreated sleep apnea

• Antineoplastic, immunosuppressive, or immune modulating therapies

• History of macular edema or uveitis

• Known IQ < 70

• Current active fungal or viral infection

• Current DSM IV-TR diagnosis of substance dependence (excluding caffeine and nicotine)

• Positive urine toxicology screen for the following: cocaine, barbiturates, methamphetamine, opiate, methadone, phencyclidine, or amphetamine prior to randomization

• Test positive for (1) Hep C virus antibody, (2) Hep B surface antigen (HBsAg) with or without positive Hep B core total antibody, (3) HIV 1 or 2 antibodies, or (4) Mantoux tuberculin test.

• Moderate to severe renal impairment as defined by creatinine clearance < 60 ml/min at screening

• Hepatic impairment as defined by liver transaminases or total bilirubin > 3 × upper limit of normal

• Subjects considered a high risk for suicidal acts - active suicidal ideation OR any suicide attempt in 90 days prior to screening

• Subjects who have participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to screening OR Subjects currently receiving treatment (within 1 dosing interval + 4 weeks) with an investigational depot formulation of an antipsychotic medication

• Subjects who demonstrate overtly aggressive behavior or who are deemed to pose a homicidal risk in the investigator's opinion

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Center for NeuroImaging	Indianapolis	Indiana	United States	46202
2	Prevention and Recovery Center	Indianapolis	Indiana	United States	46202
3	Larue D Carter Memorial Hospital	Indianapolis	Indiana	United States	46222

Sponsors and Collaborators

• Indiana University

Investigators

• Principal Investigator: Alan Breier, MD, Indiana University
• Principal Investigator: Michael Francis, MD, Indiana University

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Feb 25, 2016

More Information

Additional Information:

• Indiana University Psychotic Disorders Program

Publications

None provided.

• Responsible Party: Alan Breier, Psychiatrist, Indiana University
• ClinicalTrials.gov Identifier: NCT01779700
• Other Study ID Numbers: 11T-001
• First Posted: Jan 30, 2013
• Last Update Posted: Apr 16, 2019
• Last Verified: Mar 1, 2019

• Keywords provided by Alan Breier, Psychiatrist, Indiana University: psychosis; schizophrenia; cognition; fingolimod
• Additional relevant MeSH terms: Schizophrenia; Fingolimod Hydrochloride

Study Results

Participant Flow

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Period Title: Overall Study
STARTED	18	22
COMPLETED	14	17
NOT COMPLETED	4	5

Baseline Characteristics

Arm/Group Title	Fingolimod	Placebo	Total
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle	Total of all reporting groups
Overall Participants	18	22	40
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	18 100%	22 100%	40 100%
>=65 years	0 0%	0 0%	0 0%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	36.33 (10.28)	37.00 (13.19)	36.70 (11.83)
Sex: Female, Male (Count of Participants)
Female	6 33.3%	6 27.3%	12 30%
Male	12 66.7%	16 72.7%	28 70%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	2 11.1%	1 4.5%	3 7.5%
Not Hispanic or Latino	16 88.9%	21 95.5%	37 92.5%
Unknown or Not Reported	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	1 4.5%	1 2.5%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	9 50%	12 54.5%	21 52.5%
White	8 44.4%	8 36.4%	16 40%
More than one race	1 5.6%	1 4.5%	2 5%
Unknown or Not Reported	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	18 100%	22 100%	40 100%

Outcome Measures

1. Primary Outcome

Title	QTcB Change
Description	To determine the safety of fingolimod, as measured by the electrocardiogram (ECG) QT interval corrected by Bazett's (QTcB) value.
Time Frame	Screening, Day 0, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 84, Day 112

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
QTcB - Screening	416.50 (19.24)	416.41 (17.69)
QTcB - Day 0	418.39 (23.47)	423.27 (22.05)
QTcB - Day 7	415.50 (16.71)	417.00 (19.99)
QTcB - Day 14	418.28 (16.30)	420.15 (16.24)
QTcB - Day 21	419.67 (18.90)	412.00 (19.25)
QTcB - Day 28	424.06 (17.51)	415.74 (18.26)
QTcB - Day 35	426.18 (25.31)	419.00 (20.47)
QTcB - Day 42	425.53 (22.10)	414.33 (17.81)
QTcB - Day 49	420.79 (24.50)	413.53 (18.02)
QTcB - Day 56	420.67 (21.25)	418.41 (18.38)
QTcB - Day 84	421.50 (26.18)	420.68 (22.69)
QTcB - Day 112	419.67 (20.22)	418.58 (18.88)

2. Primary Outcome

Title	Levels of Lymphocyte
Description	To determine the safety of fingolimod, as measured by the absolute lymphocyte count
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
Absolute lymphocyte count - Baseline	1.99 (0.57)	1.97 (0.64)
Absolute lymphocyte count - 4 weeks	0.44 (0.22)	1.94 (0.47)
Absolute lymphocyte count - 8 weeks	0.49 (0.32)	2.00 (0.76)

3. Primary Outcome

Title	Symptom Changes - PANSS Total Score
Description	The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview, containing 30 items that assess symptoms of psychotic disorders including positive, negative, and general psychopathology symptoms. Positive symptoms are rated on 7 items, negative symptoms are rated on 7 items, and general psychopathology on 16 items. Scores for each item range from 1=absent to 7=extreme. Positive, negative, and general psychopathology symptoms can each respectively render total scores. Positive total scores ranging from 7-49, negative total scores ranging from 7-49, and general psychopathology scores ranging from 16-112. When all items are summed together a total score is generated. Total scores for all items range from 30-210, a lower score reflecting fewer symptoms.
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
PANSS Total Score - Baseline	48.89 (11.58)	56.50 (11.17)
PANSS Total Score - 4 weeks	49.78 (14.69)	53.60 (12.17)
PANSS Total Score - 8 weeks	49.06 (14.65)	54.94 (11.53)

4. Secondary Outcome

Title	Verbal Memory - BACS
Description	The Brief Assessment of Cognition in Schizophrenia (BACS) is a battery specifically designed to measure treatment-related changes in cognition. The BACS utilizes 6 tasks, and has alternate forms, thus minimizing practice effects. Each task generates a raw score (with a higher score indicating better performance): verbal memory 0-75; digit sequencing 0-28; token motor task 0-100; semantic&letter fluency 0-148; symbol coding 0-110; and tower of London 0-22. The raw scores are used to generate a composite score that is calculated by summing t-scores derived by comparisons with a normative sample of 404 healthy controls. The six brief assessments' t-scores, are summed, and averaged to provide a composite t-score. The composite score min and max are between -43 and 100. A higher score indicating better cognitive performance.
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
BACS Verbal Memory - Baseline	30.89 (9.61)	37.45 (11.65)
BACS Verbal Memory - 4 weeks	33.50 (8.87)	35.45 (9.56)
BACS Verbal Memory - 8 weeks	34.69 (10.62)	36.11 (11.53)

5. Secondary Outcome

Title	Cognition Change - BACS
Description	The Brief Assessment of Cognition in Schizophrenia (BACS) is a battery specifically designed to measure treatment-related changes in cognition by utilizing 6 tasks, and has alternate forms, thus minimizing practice effects. Each task generates a raw score (with a higher score indicating better performance): verbal memory 0-75; digit sequencing 0-28; token motor task 0-100; semantic&letter fluency 0-148; symbol coding 0-110; and tower of London 0-22. The raw scores are used to generate a composite score that is calculated by summing t-scores derived by comparisons with a normative sample of 404 healthy controls. The six brief assessments' t-scores, are summed, and averaged to provide a composite t-score. The composite score min and max are between -43 and 100. A higher score indicating better cognitive performance.
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
BACS Composite Score - Baseline	25.17 (14.75)	30.95 (9.48)
BACS Composite Score - 4 weeks	27.67 (13.61)	32.10 (10.64)
BACS Composite Score - 8 weeks	31.13 (12.52)	33.50 (11.45)

6. Secondary Outcome

Title	Cognition Change - Trails B
Description	The Trail Making Test-Part B (Trails B) is a measure of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive targets on a sheet of paper. In Part B version the subject alternates between numbers and letters (1, A, 2, B, etc.) The goal of the test is for the subject is to finish part B as quickly as possible, the time taken to complete the test is used as the primary performance metric. The score is the number of seconds it took to complete the test.
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
Trails B - Baseline	108.00 (51.86)	123.64 (71.11)
Trails B - 4 weeks	97.88 (40.57)	100.60 (48.02)
Trails B - 8 weeks	84.53 (28.79)	102.33 (74.48)

7. Secondary Outcome

Title	Positive Symptom Change - PANSS
Description	The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview, containing 30 items that assess symptoms of psychotic disorders including positive, negative, and general psychopathology symptoms. Positive symptoms are rated on 7 items, negative symptoms are rated on 7 items, and general psychopathology on 16 items. Scores for each item range from 1=absent to 7=extreme. Positive, negative, and general psychopathology symptoms can each respectively render total scores. Positive total scores ranging from 7-49, negative total scores ranging from 7-49, and general psychopathology scores ranging from 16-112. When all items are summed together a total score is generated. Total scores for all items range from 30-210, a lower score reflecting fewer symptoms.
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
PANSS Positive Score - Baseline	10.83 (4.94)	13.64 (5.59)
PANSS Positive Score - 4 weeks	11.89 (6.24)	14.00 (5.52)
PANSS Positive Score - 8 weeks	10.06 (4.74)	13.06 (5.40)

8. Secondary Outcome

Title	Negative Symptom Change - PANSS
Description	The Positive and Negative Syndrome Scale (PANSS) is a semi-structured interview, containing 30 items that assess symptoms of psychotic disorders including positive, negative, and general psychopathology symptoms. Positive symptoms are rated on 7 items, negative symptoms are rated on 7 items, and general psychopathology on 16 items. Scores for each item range from 1=absent to 7=extreme. Positive, negative, and general psychopathology symptoms can each respectively render total scores. Positive total scores ranging from 7-49, negative total scores ranging from 7-49, and general psychopathology scores ranging from 16-112. When all items are summed together a total score is generated. Total scores for all items range from 30-210, a lower score reflecting fewer symptoms.
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
PANSS Negative Score - Baseline	15.00 (4.79)	16.59 (5.32)
PANSS Negative Score - 4 weeks	13.89 (3.53)	14.80 (5.20)
PANSS Negative Score - 8 weeks	15.44 (4.35)	15.06 (4.67)

9. Secondary Outcome

Title	Plasma Cytokines Levels - IL-10
Description	To assess IL-10 plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL10 - Baseline	16.11 (20.81)	11.94 (13.38)
IL10 - 4 weeks	15.50 (20.67)	9.23 (10.68)
IL10 - 8 weeks	16.28 (20.96)	10.42 (9.84)

10. Secondary Outcome

Title	Plasma Cytokines Levels - IL-17A
Description	To assess IL-17A plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL17A - Baseline	3.09 (3.03)	3.72 (6.87)
IL17A - 4 weeks	2.58 (2.39)	2.43 (2.15)
IL17A - 8 weeks	2.58 (2.36)	2.69 (2.27)

11. Secondary Outcome

Title	Plasma Cytokines Levels - IL-1BETA
Description	To assess IL-1BETA plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL1BETA - Baseline	0.87 (0.81)	0.69 (0.53)
IL1BETA - 4 weeks	0.81 (0.82)	0.72 (0.63)
IL1BETA - 8 weeks	0.82 (0.76)	0.74 (0.68)

12. Secondary Outcome

Title	Plasma Cytokines Levels - IL-2
Description	To assess IL-2 plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL2 - Baseline	1.74 (2.42)	1.27 (1.43)
IL2 - 4 weeks	1.96 (2.95)	1.20 (1.63)
IL2 - 8 weeks	1.77 (2.55)	1.20 (1.24)

13. Secondary Outcome

Title	Plasma Cytokines Levels - IL-4
Description	To assess IL-4 plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL4 - Baseline	30.99 (30.86)	30.74 (33.76)
IL4 - 4 weeks	27.40 (23.61)	31.34 (31.24)
IL4 - 8 weeks	24.20 (24.57)	32.16 (34.78)

14. Secondary Outcome

Title	Plasma Cytokines Levels - IL-6
Description	To assess IL-6 plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL6 - Baseline	2.15 (2.28)	1.90 (1.75)
IL6 - 4 weeks	2.22 (2.62)	1.81 (1.99)
IL6 - 8 weeks	2.16 (2.66)	1.96 (1.56)

15. Secondary Outcome

Title	Plasma Cytokines Levels - IL-8
Description	To assess IL-8 plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IL8 - Baseline	4.29 (5.55)	3.83 (4.63)
IL8 - 4 weeks	3.81 (3.71)	3.69 (4.28)
IL8 - 8 weeks	4.18 (4.77)	3.69 (4.00)

16. Secondary Outcome

Title	Plasma Cytokines Levels - TNFa
Description	To assess TNFa plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
TNFa - Baseline	2.11 (2.16)	1.76 (1.32)
TNFa - 4 weeks	2.02 (2.77)	1.86 (1.38)
TNFa - 8 weeks	2.00 (2.19)	1.61 (1.09)

17. Secondary Outcome

Title	Plasma Cytokines Levels - IFNgamma
Description	To assess IFNgamma plasma cytokines levels changes in participants taking fingolimod versus placebo
Time Frame	Baseline, 4 weeks, 8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Fingolimod	Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle	placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
Measure Participants	18	22
IFNgamma - Baseline	5.32 (4.17)	8.32 (16.21)
IFNgamma - 4 weeks	4.61 (3.54)	4.95 (3.70)
IFNgamma - 8 weeks	4.32 (3.38)	5.62 (4.40)

Adverse Events

Time Frame	Screening through day 112
Arm/Group Title	Fingolimod		Placebo
Arm/Group Description	0.5mg of fingolimod, oral administration, daily, for 8 weeks. Fingolimod: 0.5mg each day of 8 week cycle		placebo, oral administration, daily, for 8 weeks. placebo: 1 tablet each day of 8 week cycle
All Cause Mortality
	Fingolimod		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/18 (0%)		0/22 (0%)
Serious Adverse Events
	Fingolimod		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/18 (0%)		2/22 (9.1%)
Psychiatric disorders
Hospitalization for exacerbation of schizophrenia	0/18 (0%)	0	1/22 (4.5%)	1
Respiratory, thoracic and mediastinal disorders
Pneumonia	0/18 (0%)	0	1/22 (4.5%)	1
Other (Not Including Serious) Adverse Events
	Fingolimod		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	18/18 (100%)		13/22 (59.1%)
Blood and lymphatic system disorders
Hyponatremia	0/18 (0%)	0	3/22 (13.6%)	3
Lymphocytopenia	18/18 (100%)	18	1/22 (4.5%)	1
Neutropenia	2/18 (11.1%)	2	0/22 (0%)	0
Cardiac disorders
Asymptomatic Bradycardia	3/18 (16.7%)	3	3/22 (13.6%)	4
QTc Interval Prolongation	2/18 (11.1%)	2	0/22 (0%)	0
Mobitz I AV Block	1/18 (5.6%)	1	0/22 (0%)	0
Sinus Tachycardia	1/18 (5.6%)	1	1/22 (4.5%)	1
Hypertension, intermittent	1/18 (5.6%)	1	0/22 (0%)	0
Eye disorders
Blurry vision	3/18 (16.7%)	3	0/22 (0%)	0
Gastrointestinal disorders
diarrhea	3/18 (16.7%)	3	2/22 (9.1%)	2
Nausea	1/18 (5.6%)	1	0/22 (0%)	0
General disorders
headache	3/18 (16.7%)	3	2/22 (9.1%)	2
Dry mouth	2/18 (11.1%)	2	0/22 (0%)	0
Exacerbation of Allergic Rhinitis	1/18 (5.6%)	1	0/22 (0%)	0
Insomnia	1/18 (5.6%)	1	0/22 (0%)	0
mood lability	1/18 (5.6%)	1	0/22 (0%)	0
Fatigue	1/18 (5.6%)	1	0/22 (0%)	0
Paresthesia	1/18 (5.6%)	1	1/22 (4.5%)	1
Stuttering	1/18 (5.6%)	1	0/22 (0%)	0
Dyskinetic Movement	1/18 (5.6%)	1	0/22 (0%)	0
Hepatobiliary disorders
Elevated Liver Enzymes	5/18 (27.8%)	5	0/22 (0%)	0
Musculoskeletal and connective tissue disorders
Low back pain	1/18 (5.6%)	1	1/22 (4.5%)	2
Chest wall pain	1/18 (5.6%)	1	0/22 (0%)	0
Psychiatric disorders
Increased auditory hallucinations	1/18 (5.6%)	1	0/22 (0%)	0
Worsening of intermittent panic attacks	1/18 (5.6%)	1	0/22 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.